Skip to main content

West Pharmaceutical Services income statement

  • WST · NYSE
  • Medical devices
  • Health Care Supplies
  • S&P 500
$416.42+1.24%Close 13 Nov 2026

West Pharmaceutical Services reported revenue of $3.07 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 6.3% from fiscal 2024. Net income was $494 million and diluted earnings per share $6.79.

From West Pharmaceutical Services's annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 31 Dec 2025. TTM is the last four reported quarters added up.

Annual

West Pharmaceutical Services income statement, annual
USDFY 2008FY 2009FY 2010FY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Revenue$1.05B$1.06B$1.10B$1.19B$1.27B$1.37B$1.42B$1.40B$1.51B$1.60B$1.72B$1.84B$2.15B$2.83B$2.89B$2.95B$2.89B$3.07B$3.40B
Revenue growth—+0.4%+4.6%+7.9%+6.2%+8.1%+3.9%−1.5%+7.8%+6.0%+7.4%+7.1%+16.7%+31.9%+2.0%+2.2%−1.9%+6.3%—
Net interest income——−$16.20M−$16.90M−$14.90M−$15.10M−$13.00M−$12.50M−$7.00M−$6.50M—————————
Cost of revenue$748.5M$752.1M$786.6M$853.0M$878.7M$933.7M$973.6M$944.0M$1.01B$1.09B$1.17B$1.23B$1.38B$1.66B$1.75B$1.82B$1.89B$1.97B$2.12B
Gross profit$302.6M$303.6M$318.1M$339.3M$387.7M$434.7M$447.8M$455.8M$501.4M$512.9M$545.4M$605.7M$767.8M$1.18B$1.14B$1.13B$998.5M$1.10B$1.28B
Gross margin28.8%28.8%28.8%28.5%30.6%31.8%31.5%32.6%33.2%32.1%31.8%32.9%35.8%41.5%39.4%38.3%34.5%35.9%37.6%
Research and development$18.70M$19.90M$23.90M$29.10M$33.20M$37.90M$37.30M$34.10M$36.80M$39.10M$40.30M$38.90M$46.90M$52.80M$58.50M$68.40M$69.10M$74.30M$75.60M
Selling, general and administrative$159.3M$177.7M$187.7M$191.1M$218.1M$234.9M$228.7M$233.0M$239.6M$246.0M$262.9M$272.7M$302.0M$362.8M$316.9M$353.4M$338.5M$393.6M$437.0M
Operating expenses$178.5M———$252.6M$272.3M$265.8M——$287.1M$305.1M$309.1M—$423.5M—————
Operating income$124.1M$97.50M$90.70M$109.6M$135.1M$162.4M$182.0M$128.6M$195.2M$225.8M$240.3M$296.6M$406.9M$752.3M$734.0M$676.0M$569.9M$584.9M$780.2M
Operating margin11.8%9.2%8.2%9.2%10.7%11.9%12.8%9.2%12.9%14.1%14.0%16.1%19.0%26.6%25.4%22.9%19.7%19.0%23.0%
Interest expense$16.00M$15.20M$16.80M$18.20M$16.70M$17.00M$16.50M$14.10M$8.10M$7.80M$8.40M$8.50M$8.20M$8.20M$7.90M$9.00M$3.00M$500.0K$8.50M
Other income and expense——————————$400.0K−$4.80M−$5.60M−$3.40M−$54.10M$22.00M———
Income before tax$109.5M$83.10M$74.50M$92.70M$108.6M$147.1M$169.0M$116.1M$189.8M$222.4M$240.7M$291.8M$401.3M$748.9M$679.9M$698.0M$585.5M$600.9M$789.4M
Income tax expense$23.70M$13.50M$13.60M$23.50M$32.70M$40.20M$47.20M$26.30M$54.40M$80.90M$41.40M$59.00M$72.50M$107.2M$114.7M$122.3M$107.5M$121.6M$168.2M
Effective tax rate21.6%16.2%18.3%25.4%30.1%27.3%27.9%22.7%28.7%36.4%17.2%20.2%18.1%14.3%16.9%17.5%18.4%20.2%21.3%
Net income$86.00M$72.60M$65.30M$75.50M$80.70M$112.3M$127.1M$95.60M$143.6M$150.7M$206.9M$241.7M$346.2M$661.8M$585.9M$593.4M$492.7M$493.7M$638.9M
Net margin8.2%6.9%5.9%6.3%6.4%8.2%8.9%6.8%9.5%9.4%12.0%13.1%16.1%23.4%20.3%20.1%17.0%16.1%18.8%
Net income to common shareholders——$69.60M$79.80M$82.70M$112.3M$127.1M————————————
EPS · diluted$1.19$1.00$0.95$1.08$1.15$1.57$1.75$1.30$1.91$1.99$2.74$3.21$4.57$8.67$7.73$7.88$6.69$6.79$8.90
Diluted weighted average shares72.2M72.6M73.4M74.0M71.8M71.4M72.8M73.8M75.0M75.8M75.4M75.4M75.8M76.3M75.8M75.3M73.7M72.7M71.8M
Basic weighted average shares64.8M65.6M66.6M67.3M68.1M69.6M70.9M72.0M73.3M73.9M73.9M74.0M73.9M74.4M74.4M74.3M73.0M72.3M71.4M
EBITDA$180.2M$161.4M$163.6M$185.3M$212.0M$247.6M$272.0M$218.5M$285.9M$322.5M$344.7M$400.0M$516.0M$874.6M$854.6M$813.3M$725.3M$756.3M$964.5M
EBITDA margin17.1%15.3%14.8%15.5%16.7%18.1%19.1%15.6%18.9%20.2%20.1%21.7%24.0%30.9%29.6%27.6%25.1%24.6%28.4%
Depreciation & amortization$56.10M$63.90M$72.90M$75.70M$76.90M$85.20M$90.00M$89.90M$90.70M$96.70M$104.4M$103.4M$109.1M$122.3M$120.6M$137.3M$155.4M$171.4M$184.3M
Stock-based compensation$6.40M$7.50M$7.80M$8.40M$15.50M$21.20M$18.60M$29.60M$19.50M$16.10M$15.10M$24.40M$34.00M$37.50M$23.70M$23.30M$18.70M$23.80M$28.50M
Dividends per share$0.29$0.31$0.33$0.35$0.37$0.39$0.41$0.46$0.50$0.54$0.58$0.62$0.66$0.70$0.74$0.78$0.82$0.86—

Quarterly

West Pharmaceutical Services income statement, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$732.0M$695.4M$702.1M$746.9M$748.8M$698.0M$766.5M$804.6M$805.0M$844.9M$872.3M$874.5M
Cost of revenue$453.8M$465.2M$472.1M$482.2M$475.2M$466.1M$492.6M$510.3M$501.1M$548.5M$543.1M$527.1M
Gross profit$278.2M$230.2M$230.0M$264.7M$273.6M$231.9M$273.9M$294.3M$303.9M$296.4M$329.2M$347.4M
Gross margin38.0%33.1%32.8%35.4%36.5%33.2%35.7%36.6%37.8%35.1%37.7%39.7%
Research and development$18.40M$17.60M$17.50M$15.50M$18.50M$16.30M$19.10M$17.10M$21.80M$15.80M$19.70M$18.30M
Selling, general and administrative$90.00M$86.70M$83.00M$83.50M$85.30M$88.00M$95.90M$102.7M$107.0M$99.50M$117.6M$112.9M
Operating income$160.9M$122.8M$126.2M$161.3M$159.6M$107.0M$153.7M$167.6M$156.6M$177.1M$179.1M$267.4M
Operating margin22.0%17.7%18.0%21.6%21.3%15.3%20.1%20.8%19.5%21.0%20.5%30.6%
Interest expense$1.20M$1.60M$1.50M$700.0K$800.0K$400.0K$100.0K$200.0K$200.0K$1.90M$2.60M$3.80M
Other income and expense$7.30M$4.60M$2.50M$3.20M————————
Income before tax$168.2M$127.4M$128.7M$164.5M$164.9M$110.5M$157.0M$171.9M$161.5M$180.1M$180.1M$267.7M
Income tax expense$34.50M$16.40M$21.90M$32.40M$36.80M$24.10M$30.20M$34.00M$33.30M$44.70M$32.20M$58.00M
Effective tax rate20.5%12.9%17.0%19.7%22.3%21.8%19.2%19.8%20.6%24.8%17.9%21.7%
Net income$137.0M$115.3M$111.3M$136.0M$130.1M$89.80M$131.8M$140.0M$132.1M$138.8M$154.0M$214.0M
Net margin18.7%16.6%15.9%18.2%17.4%12.9%17.2%17.4%16.4%16.4%17.7%24.5%
EPS · diluted$1.83$1.55$1.51$1.85$1.77$1.23$1.82$1.92$1.82$1.92$2.15$3.02
Diluted weighted average shares74.7M74.3M73.7M73.4M73.4M73.0M72.5M72.6M72.7M72.4M71.3M70.8M
Basic weighted average shares74.0M73.5M73.0M72.8M72.7M72.5M72.2M72.2M72.3M72.0M70.8M70.4M
EBITDA$196.8M$158.4M$165.1M$201.5M$200.3M$147.0M$195.1M$210.6M$203.6M$222.3M$225.3M$313.3M
EBITDA margin26.9%22.8%23.5%27.0%26.7%21.1%25.5%26.2%25.3%26.3%25.8%35.8%
Depreciation & amortization$35.90M$35.60M$38.90M$40.20M$40.70M$40.00M$41.40M$43.00M$47.00M$45.20M$46.20M$45.90M
Stock-based compensation$1.40M$5.00M$4.30M$5.10M$4.30M$1.30M$7.40M$8.40M$6.70M$6.60M$10.90M$4.30M
Dividends per share—$0.20$0.20——$0.21$0.21$0.22$0.22$0.22—$0.22

The main figures as JSON and plain text. See data and methodology.

WST in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.